138 related articles for article (PubMed ID: 6144318)
1. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
Dew MJ; Ebden P; Kidwai NS; Lee G; Evans BK; Rhodes J
Br J Clin Pharmacol; 1984 Apr; 17(4):474-6. PubMed ID: 6144318
[TBL] [Abstract][Full Text] [Related]
2. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
Donald IP; Wilkinson SP
Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
[TBL] [Abstract][Full Text] [Related]
3. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.
Myers B; Evans DN; Rhodes J; Evans BK; Hughes BR; Lee MG; Richens A; Richards D
Gut; 1987 Feb; 28(2):196-200. PubMed ID: 3557190
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
Corey AE; Rose GM; Conklin JD
J Int Med Res; 1990; 18(6):441-53. PubMed ID: 1981363
[TBL] [Abstract][Full Text] [Related]
6. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.
Dew MJ; Ryder RE; Evans N; Evans BK; Rhodes J
Br J Clin Pharmacol; 1983 Aug; 16(2):185-7. PubMed ID: 6615691
[TBL] [Abstract][Full Text] [Related]
7. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic study of sulphasalazine and two new formulations of mesalazine.
Swift GL; Mills CM; Rhodes J; Evans BK; Bennett A; Tavares IA
Aliment Pharmacol Ther; 1992 Apr; 6(2):259-66. PubMed ID: 1350926
[TBL] [Abstract][Full Text] [Related]
9. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
Rutgeerts P
Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
[TBL] [Abstract][Full Text] [Related]
11. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.
Fischer C; Maier K; Stumpf E; von Gaisberg U; Klotz U
Eur J Clin Pharmacol; 1983; 25(4):511-5. PubMed ID: 6140167
[TBL] [Abstract][Full Text] [Related]
12. Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils.
Williams JG; Hallett MB
Gut; 1989 Nov; 30(11):1581-7. PubMed ID: 2574700
[TBL] [Abstract][Full Text] [Related]
13. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
Nakshabendi IM; Duncan A; Russell RI
Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
[TBL] [Abstract][Full Text] [Related]
14. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.
Dew MJ; Hughes P; Harries AD; Williams G; Evans BK; Rhodes J
Br Med J (Clin Res Ed); 1982 Oct; 285(6347):1012. PubMed ID: 6127137
[No Abstract] [Full Text] [Related]
16. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.
Azad Khan AK; Nurazzaman M; Truelove SC
J Med Genet; 1983 Feb; 20(1):30-6. PubMed ID: 6133000
[TBL] [Abstract][Full Text] [Related]
17. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
Ardizzone S; Petrillo M; Molteni P; Desideri S; Bianchi Porro G
J Clin Gastroenterol; 1995 Dec; 21(4):287-9. PubMed ID: 8583101
[TBL] [Abstract][Full Text] [Related]
18. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.
Mardini HA; Lindsay DC; Deighton CM; Record CO
Gut; 1987 Sep; 28(9):1084-9. PubMed ID: 3678967
[TBL] [Abstract][Full Text] [Related]
19. 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa.
Bondesen S; Tage-Jensen U; Jacobsen O; Hansen SH; Rasmussen SN; Hvidberg EF
Eur J Clin Pharmacol; 1986; 31(1):23-6. PubMed ID: 2877884
[TBL] [Abstract][Full Text] [Related]
20. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
Rijk MC; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1988 Jan; 23(1):107-12. PubMed ID: 2894070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
